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Abstract
Background and Objective: A high proportion of low-income people insured by the Medicaid program smoke. Earlier
research concerning a comprehensive tobacco cessation program implemented by the state of Massachusetts indicated
that it was successful in reducing smoking prevalence and those who received tobacco cessation benefits had lower rates of
in-patient admissions for cardiovascular conditions, including acute myocardial infarction, coronary atherosclerosis and nonspecific chest pain. This study estimates the costs of the tobacco cessation benefit and the short-term Medicaid savings
attributable to the aversion of inpatient hospitalization for cardiovascular conditions.
Methods: A cost-benefit analysis approach was used to estimate the program’s return on investment. Administrative data
were used to compute annual cost per participant. Data from the 2002–2008 Medical Expenditure Panel Survey and from
the Behavioral Risk Factor Surveillance Surveys were used to estimate the costs of hospital inpatient admissions by Medicaid
smokers. These were combined with earlier estimates of the rate of reduction in cardiovascular hospital admissions
attributable to the tobacco cessation program to calculate the return on investment.
Findings: Administrative data indicated that program costs including pharmacotherapy, counseling and outreach costs
about $183 per program participant (2010 $). We estimated inpatient savings per participant of $571 (range $549 to $583).
Every $1 in program costs was associated with $3.12 (range $3.00 to $3.25) in medical savings, for a $2.12 (range $2.00 to
$2.25) return on investment to the Medicaid program for every dollar spent.
Conclusions: These results suggest that an investment in comprehensive tobacco cessation services may result in
substantial savings for Medicaid programs. Further federal and state policy actions to promote and cover comprehensive
tobacco cessation services in Medicaid may be a cost-effective approach to improve health outcomes for low-income
populations.
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Medicaid expenditures, representing an estimated $22 billion in
2004 [5].
Federal policy has sought to reduce smoking by Medicaid
beneficiaries as an important public health goal. For instance, one
of the key objectives of Healthy People 2020 is to ‘‘increase
comprehensive Medicaid insurance coverage of evidence-based
treatment for nicotine dependency in States and the District of
Columbia [6].’’ Considerable efforts have been made at the state
level to reduce smoking. In 2009, Medicaid programs in 47 states
and the District of Columbia offered at least some form of
coverage for tobacco-dependence treatments, although most had a
limited range of benefits [7]. The Patient Protection and
Affordable Care Act will increase this coverage; it requires all
states to offer comprehensive tobacco cessation services for
pregnant women as of 2010 (Section 4107 of the Act) and to

Introduction
Smoking is a leading cause of preventable death in the United
States, resulting in an estimated 450,000 annual premature deaths,
or nearly one of every five deaths. It is responsible for roughly 30%
of all cancer deaths, for nearly 80% of deaths from chronic
obstructive pulmonary disease, and for early cardiovascular
disease deaths [1–3]. More than one-third of the smokingattributable years of potential life lost are related to cardiovascular
disease [4]. The annual economic burden of smoking in the U.S.
has been estimated at nearly $193 billion in direct medical costs
and productivity losses [2]. While the life-time prevalence rate for
adult smokers in the U.S. population is about 20% of this rate is
about twice as high among adults insured by Medicaid [1–3].
Smoking-related medical costs are responsible for 11% of
PLoS ONE | www.plosone.org
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cover anti-smoking medications under Medicaid by 2014 (Section
2502).
The state of Massachusetts initiated early efforts to provide
comprehensive tobacco cessation medications and services to lowincome Medicaid enrollees under its Tobacco Cessation &
Prevention Program, starting in 2006. Under the program, with
a physician’s prescription, Medicaid beneficiaries could obtain
FDA-approved smoking cessation medications with a copayment
ranging from $1 to $3 per month. No preauthorization was
required for a nicotine patch, gum or lozenge, bupropion (e.g.,
Zyban) or varenicline (Chantix) [8]. Massachusetts also offered up
to five sessions of free telephone counseling for the state’s quit line
(although this was not required to get medications).
Research by Thomas Land, et al. found that this program
reached a substantial share of smokers in Medicaid, achieving
about a 37% use rate, and was successful in contributing to a 10%
reduction in the rate of smoking by Medicaid beneficiaries [9].
Further analyses by Land, et al. examined the inpatient hospital
utilization of Medicaid enrollees who used the smoking cessation
benefit. The study used generalized estimating equations to
examine changes in hospitalization trends among 21,656 Medicaid beneficiaries before and after the use of the tobacco cessation
benefit, adjusting for demographics, comorbidities, seasonality,
and other factors. On average, study participants were followed
over four years, with 70 weeks in the post-benefit period. The
study found that participation in the program was associated with
statistically significant reductions of 46% in hospital inpatient
admissions for acute myocardial infarction (AMI) (p,.05), 49% for
coronary atherosclerosis and other heart disease (p,.05), and 32%
for non-specific chest pain (p,.1), relative to the rate without the
benefit [10]. There were no significant differences in hospitalizations for respiratory conditions or other seven other diagnostic
groups evaluated.
In this study, we estimated the economic value of Massachusetts’
tobacco cessation program’s reduction on cardiovascular hospitalizations relative to program costs. We use the estimate of reductions
in cardiovascular hospitalizations reported in Land’s inpatient study
[10]. Previous research has examined the efficacy of smoking
cessation methods and found that pharmacotherapy can be a costeffective treatment modality [11–18]. A recent study by Ladapo
simulated the lifetime cost-effectiveness of a smoking counseling
program for smokers hospitalized with AMI and concluded that
counseling would reduce hospitalization costs but might increase
lifetime healthcare costs by extending longevity [19]. In contrast,
our study focuses on prevention of cardiovascular problems among
smokers prior to hospitalization, primarily using pharmacotherapy,
and focuses on short-term costs and savings, as opposed to lifetime
cost-effectiveness. This study does not seek to measure all potential
long-term savings due to the implementation of the tobacco
cessation program, but represents a conservative estimate of shortterm savings solely related to the avoidance of inpatient hospital
admissions and treatment of cardiovascular diseases among
Massachusetts Medicaid beneficiaries and smokers.

Study Design and Analytical Framework
This study uses cost-benefit analysis to estimate short-term ROI of
the Massachusetts tobacco cessation benefit, based on estimated
program costs and savings attributable to reduced cardiovascular
admissions among adult Medicaid enrollees. We used a blend of
national and state data to estimate costs and savings, as described in
the data section below. National data sources include the Medical
Expenditure Panel Survey (MEPS), while state data include
administrative program cost data, the Massachusetts Behavioral Risk
Factor Surveillance System, and the Massachusetts hospital reduction
estimates of Land, et al [10]. Figure 1 is a flowchart that summarizes
the stages of this analysis and the data sources used at each stage.

Patient Population
The patient population is limited to Massachusetts Medicaid
beneficiaries aged 18 to 64 years who are smokers. We excluded
those enrolled in both Medicaid and Medicare (also known as
‘‘dual eligibles’’), since most of their inpatient costs are paid by
Medicare. The MEPS analytic sample included 805 Medicaid
beneficiaries who are smokers. Smokers were defined as those who
reported that they are current smokers as of the last year of
participation in the survey.

Analytical Horizon, Perspective, and Setting of the Study
Land’s study examined changes in hospital admissions in the
period before and after use of tobacco cessation benefits; on
average, patients were followed for 70 weeks after they began
using tobacco cessation medications [10]. Thus, the time horizon
of potential savings is about 1.3 years after the receipt of benefits.
Our study does not seek to extrapolate longer term benefits
associated with smoking reduction. Nor does it seek to extrapolate
to benefits beyond reduced hospitalizations for cardiovascular
conditions among Medicaid beneficiaries that smoke. Examples of
benefits omitted from this analysis include benefits for other
averted diseases, increases in worker productivity, and potential
life years saved. It focuses on costs and savings incurred by the
Medicaid program in Massachusetts.

Clinical Benefits and Economic Measures
Our primary clinical benefits are reduced admissions for certain
cardiovascular diseases. Land, et al. grouped inpatient admissions
into groups that had been defined by the Healthcare Utilization
Project (HCUP) using clinical classification software (CCS) codes
of 100 for acute myocardial infarction (AMI), 101 for coronary
atherosclerosis and other heart disease, and 102 for non-specific
chest pain. The same system is used in the MEPS data that we
analyzed. These group codes are based on numerous specific
CPT-9-CM procedure codes reported in hospital claims records
and grouped by the CCS system [20]. It should be noted that nonspecific chest pain may have multiple etiologies, which may
include cardiovascular problems but might also include other
problems, such as reflux disease or pleuritis. Following the CCS
and Land, et al., we classified these as cardiovascular problems,
but recognize that some could have other etiologies.
Our economic benefit data include costs to the Medicaid
program for prescription drugs and counseling costs and savings
due to averted inpatient admissions. All costs and savings were
converted to 2010 dollars using medical price inflation data from
the Bureau of Labor Statistics.

Methods
Objective
This study provides an independent estimate of cost savings and
the return on investment (ROI) associated with reductions in
inpatient hospital admissions for cardiovascular conditions by
Medicaid beneficiaries participating in the Massachusetts Tobacco
Cessation & Prevention Program from 2007 to 2009. It focuses on
the costs and savings from the perspective of the Medicaid
program.
PLoS ONE | www.plosone.org

Data Sources
A variety of data sources were used. Administrative data on
program costs were used to compute the annual average cost per
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Figure 1. Flowchart summarizing the analyses.
doi:10.1371/journal.pone.0029665.g001

individuals we were able to compute robust standard errors. The
MEPS data reflect a national sample of Medicaid smokers and is
one of the few data sets that contain expenditures. (It is worth
noting that we could not obtain hospital savings from administrative data; a substantial share of the hospital data from
Massachusetts was from managed care systems and lacked cost
or expenditure data.)
To adjust the results of the models to reflect the characteristics of
adult Medicaid beneficiaries and smokers living in Massachusetts,
we used data from the Massachusetts Department of Health’s
Behavioral Risk Factor Surveillance Survey (BRFSS) for 2007–9.
The BRFSS does not contain data on medical expenditures. The
state BRFSS survey includes some questions not included in other
states’ BRFSS data that permits identification of Medicaid smokers.
We also used the Consumer Price Index for inpatient hospital data
from the Bureau of Labor and Statistics (BLS) to inflate program
costs and economic value of program benefits to 2010 dollars.

patient in implementing the program. Data on program costs for
fiscal years 2007, 2008, and 2009 were provided by the
Massachusetts Tobacco Cessation & Prevention Program, based
on Medicaid (known as MassHealth in Massachusetts) administrative cost data. These included the cost of pharmacotherapy,
counseling, and program outreach and promotion for fiscal years
2007, 2008, and 2009.
To compute the economic value of program benefits such as
averted hospital inpatient admissions we used data from the
Medical Expenditure Panel Survey (MEPS). To increase the sample size of
the study we pooled data from the 2002–8 MEPS. MEPS is a nationally
representative survey of non-institutionalized individuals conducted by the
Agency for Healthcare Research and Quality. It is a widely used survey that
collects information on socio-demographic characteristics, health
services use, health conditions, access to care, health insurance
coverage, medical expenditures, sources of payment, and income
for each person surveyed, drawn both from surveys of individuals
and health care providers. We restricted the analytic sample to
unique individuals reported as 18 to 64 year old Medicaid
beneficiaries who were current smokers. The MEPS longitudinal
design allows repeated observations on the same individuals
several times during the year. By restricting the sample to unique
PLoS ONE | www.plosone.org

Analytical Approach and Models
Figure 1 summarizes the overall flow of analyses in this paper.
For the first stage, we estimated expenditure models for inpatient hospital
expenditures for cardiovascular conditions for adult Medicaid beneficiaries who
3
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That is, any ROI greater than zero means that more was saved (or
gained) than was spent on the initiative.
To assess the uncertainty of the estimates, we computed
different levels of ROI by using the 95% confidence intervals of
the predicted expenditures for the noted cardiovascular conditions
by adult Medicaid smokers into account. This enabled us to
compute low, medium and high estimates of the potential savings
due to reduced cardiovascular admissions.

are smokers, using MEPS data. To specify the model, we used a modified
version of Aday and Andersen’s behavioral model of factors
affecting health utilization [21]. This model hypothesizes that
utilization depends on predisposing, enabling and health need
factors. The predisposing factors included age, race/ethnicity,
gender and marital status. The enabling factors included income
as a percent of poverty, educational attainment and health
insurance status. Health need factors included self-reported health
status (fair or poor health), whether the respondent exercised and
obesity status. We also included geographic factors that may affect
use of care, including rural/urban status and Census region.
To test the robustness of the models, we tested different
specifications. We estimated a version including having a diagnosis
of diabetes as an additional health factor and a version with
diabetes and hypertension. These variables were not significant in
any of the models, so we reverted to our base models.
There are two well-recognized econometric problems in
estimating medical expenditures. The first is that there are many
zero observations leading to systematic differences in characteristics
between patients with zero expenditure compared to those with
positive expenditures. The second problem is that medical
expenditures are highly skewed because a subset of patients with
positive expenditures has very large expenditures [22–23]. Twopart models that take into consideration patients with zero
expenditures and patient with positive expenditures are typically
used to address the problem of many zero observations. However, in
our case, we only look at those who have inpatient admissions and
virtually all have non-zero expenditures. Hence, there is no need to
use the first part of the two-part model, usually logistic or probit
regressions, to account for the probability of using any medical care.
To address the skewness in expenditures, we used logtransformed generalized linear models (GLM) with log link and
Gamma distribution to estimate direct hospital inpatient expenditures associated with cardiovascular services noted above by
adult Medicaid beneficiaries who are also smokers. The log link
was incorporated into the model specifically to address the
skewness observed in the expenditures data. We developed several
models to predict total healthcare expenditures and conducted
sensitivity analyses for robustness. We used the diagnostic and
specification tests recommended by Manning and Mullahy to
select the final models [24]. Final models were adjusted for MEPS’
complex survey design and weighting, using the survey design
adjustment procedures in Stata 11.
The expenditure models using MEPS data reflect characteristics
of Medicaid smokers nationwide. In order to calibrate our
estimates to more closely correspond to Massachusetts residents,
we then used data from the Massachusetts BRFSS to identify
characteristics of adult Medicaid beneficiaries in Massachusetts.
We then adjusted our expenditure estimates based on the
demographic, socioeconomic, access, behavioral, health status
and health condition variables of Massachusetts Medicaid smokers
(see Table 1).
After that stage, we computed cost savings associated with
inpatient expenditures related reductions in AMI, acute coronary
heart disease, and non-specific chest pain among Medicaid
smokers. Costs were based on administrative data provided by
Massachusetts officials. All program costs and estimated savings
were inflated to 2010 dollars using the Consumer Price Index for
inpatient hospital costs from the Bureau of Labor Statistics.
We computed the return on investment (ROI) as:
ROI~

Results
Descriptive Statistics
In our initial analyses of the 2002–8 MEPS data, 98% of adult
Medicaid smokers 18 to 64 who had inpatient hospital admissions
also had hospital expenditures reported. (We believe that the 2%
without expenditures are due to the fact that MEPS does not
report expenditures in cases where certain hospitals provide care
without charge, on a ‘‘charity’’ basis.) The average expenditure for
a Medicaid smoker’s admission was $13,950. However, the
average adult hospital in-patient in the U.S. spent about $28,691
with AMI diagnoses, $9,828 for coronary atherosclerosis and other
heart disease, and $6,874 for non-specific chest pain.
Table 1 compares the characteristics of the overall sample of
adult Medicaid beneficiaries who were smokers at the national
level (based on MEPS data) and in Massachusetts (based on
BRFSS data), regardless of whether they had an inpatient
admission. A slightly higher proportion of Medicaid beneficiaries
residing in Massachusetts were admitted for hospital inpatient
services for AMI and coronary atherosclerosis and other heart
disease, compared to the national average. But these differences
were small and not significant. Other socio-demographic characteristics of Massachusetts Medicaid beneficiaries were similar to
the national average, except that there were a higher proportion of
males among Medicaid smokers compared to the national
average. A higher proportion of Massachusetts residents had
higher incomes or were college graduates, compared to adults at
the national level, probably because Massachusetts has more
generous Medicaid eligibility than most other states. In terms of
behavioral factors, Massachusetts residents exercised more and
reported a lower percentage of adults with obesity compared to the
U.S. (though the lower percentage of adults with obesity was offset
by higher rates over overweight). Similarly, those in the
Massachusetts Medicaid program were more likely to report that
they were in excellent, very or good health, and less likely to report
diabetes and hypertension than those at the national level.

Program Costs
As indicated in Table 2, $20,178,210 was spent for medications
or counseling under the state’s Tobacco Cessation and Prevention
Program from FY 2007 to 2009, representing an average of
$6,726,070 per year. Additionally, $558,500 was spent on
program’s promotion and outreach during the three years,
representing an average of $186,167 annually. A total of
550,067 individuals who were between 18 and 64 years old
participated in the state’s Medicaid program during fiscal years
2007–2009, of which 188,123 (34.2%) were identified as smokers.
Over 75,000 unique Medicaid beneficiaries participated in the
tobacco cessation program during the three-year period. During
2007–9, an annual average of 37,762 participants who were
smokers used medications or counseling services. The annual
average cost per user of medication and counseling services was
$178; an additional $5 was spent on program outreach and
promotion. In sum, a total of $183 was spent annually per user to
implement the program from 2007–2009.

Averted cost of hospitalization { Program cost
Program cost
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Table 1. Descriptive Characteristics of 18–64 Year Old Medicaid Beneficiaries Who are Current Smokers.

U.S.
(from MEPS)

Variables

Massachusetts (from BRFSS)

Percent Admitted to Hospital by Diagnosis Group
Acute myocardial infarction

1%

3%

Coronary atherosclerosis & other heart disease

1%

2%

Non-specific chest pain

3%

3%

37.4 years

34.5 years

Male

29%

42%

Female

71%

57%

White

69%

66%

Hispanic

10%

17%

Black or African American

20%

9%

Asian

1%

1%

Married

27%

33%

Divorced

23%

15%

Widowed

3%

2%

Separated

6%

4%

Never married

47%

44%

Demographic Variables
Mean Age
Gender

Race/Ethnicity

Marital status

Socioeconomic Status
Income as % of Poverty
0–100% of poverty

61%

63%

100–200% of poverty

23%

22%

200–400% of poverty

12%

9%

Over 400% of poverty

0.04

0.06

Less than high school degree

44%

24%

High school graduate

53%

66%

College graduate or more

03%

10%

No physical activity

59%

32%

Physical Activity

41%

68%

Normal weight

41%

39%

Overweight

24%

35%

Obese

35%

23%

Excellent/Very good/Good

54%

72%

Fair/Poor

46%

30%

No diabetes

85%

94%

Diabetes

15%

6%

Education

Behavioral Variables

Health Status

Morbidity

No Hypertension

69%

80%

Hypertension

31%

20%

Residence/Region
Non-Metropolitan Statistical Area

22%

Metropolitan Statistical Area

78%

doi:10.1371/journal.pone.0029665.t001
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Table 2. Program Costs for Adult Medicaid Smokers Who Participated in the Tobacco Cessation Program during Fiscal Years 2007–
2009 (US $ 2010).

Category of Services

Annual Average
Total Costs

Total Program Costs

Annual Average
Number of Users

Annual Average Cost per
User

Medications & counseling

$20,178,210

$6,726,070

37,762

$178

Program outreach and promotion

$558,500

$186,167

---

$5

Total

$20,736,710

$6,912,237

37,762

$183

Source: Based on authors’ calculations using data from MassHealth, Office of Clinical Affairs.
doi:10.1371/journal.pone.0029665.t002

ROI per adult Medicaid smoker in Massachusetts of $2.12, with a
range from $2.00 to about $2.25. In other words, each $1 spent on
medications and counseling, and promotion and outreach for
Medicaid smokers was associated with a reduction of $3.12 (range
$3.00 to $3.25) in Medicaid expenditures for cardiovascular
hospital admissions, resulting in net savings between $2.00 and
$2.25.
As noted earlier in this paper, it is possible that some of the
admissions due to non-specific chest pain are not actually due to
cardiovascular conditions, but disorders like reflux disease or
pleuritis. Even if we net out these savings related to non-specific
chest pain, the estimated ROI remains highly positive, ranging
from $1.63 to $1.84.

Economic Value of Hospital Inpatient Admissions for
Cardiovascular Conditions
As shown in Table 3, results from expenditure models that were
calibrated using characteristics of Medicaid smokers in Massachusetts showed adjusted inpatient expenditures of $26,044 for
AMI (95% confidence interval from $25,026 to $27,060), of
$12,760 for coronary atherosclerosis and other heart disease (95%
confidence interval from $12,260 to $13,258) and $7,367 for nonspecific chest pain (95% confidence interval from $7,086 to
$7,647). The models were adjusted for socio-demographic, socioeconomic, access, behavioral, health status and health condition
variables of Massachusetts Medicaid smokers, as described in the
methods section.
To compute the economic value of averted hospital inpatient
admissions for cardiovascular conditions by adult Medicaid
smokers in Massachusetts (or the benefits of the program), we
multiplied the adjusted inpatient expenditures of the each of the
conditions by their corresponding rate of reductions in hospital
inpatient admissions estimated by Land et al [10]: AMI (46%),
coronary atherosclerosis and other related conditions (49%) and
non-specific chest pains (32%). Subsequently, we multiplied each
of the respective results by the rate of hospital inpatient admissions
among Medicaid smokers in Massachusetts, as reported in BRFSS
(3% for AMI, 2% for coronary atherosclerosis, 3% for non-specific
chest pain). As indicated in Table 4, we found that the economic
value of averted hospital inpatient admissions for cardiovascular
conditions per adult Medicaid smoker in Massachusetts ranged
from $368 to $398 for AMI, from $113 to $117 for coronary
atherosclerosis and other heart disease, and from $68 to $78 for
non-specific chest pain. This resulted in total program benefits per
adult Medicaid smokers in Massachusetts user of $571, ranging
from $549 to $593.

Discussion
The current study advances the literature on the economic
evaluation of smoking cessation programs at the state level in the
United States. Findings from this study indicate that a wellpromoted program of comprehensive access to tobacco medications and counseling implemented in Massachusetts was cost
beneficial. Over an average of 70 weeks after beginning to use
smoking cessation medications, Medicaid beneficiaries experienced fewer hospital admissions due to cardiovascular conditions,
leading to a net annual savings of $366 to $410 per Medicaid user
or an ROI of $2.00 to $2.25 during the period of 2007–2009.
These results were adjusted for an extensive set of control
variables and the findings were robust to different model
specifications.
This study has strengths and limitations. In terms of strengths,
the study used detailed administrative data about program costs
and relied on estimates of reductions in hospital admissions
based on detailed hospital data analyzed by Land, et al [10].
Because we lacked actual administrative data on the costs of
hospitalizations averted, we used a comprehensive national data
set (MEPS) to estimate the costs of cardiovascular hospital
admissions among adult Medicaid smokers. To control for

Net Savings and Return on Investment
As reported in Table 5, we estimated net annual savings of $388
(ranging from $366 to $410) per user in Massachusetts, compared
to program costs of $183 per user. This leads to an annual average

Table 4. Estimated Annual Value of Averted Hospital
Inpatient Admissions for Cardiovascular Conditions Per User
in Massachusetts (US $ 2010).

Table 3. Estimated (Adjusted) Annual Average Expenditures
Per Inpatient for Cardiovascular Conditions for Adult Medicaid
Smokers in Massachusetts (US $ 2010).

Cardiovascular Conditions

Low

Midpoint

High

Cardiovascular conditions

Low

Midpoint

High

Acute myocardial infarction

$368

$383

$398

Acute myocardial infarction

$25,026

$26,044

$27,060

Coronary atherosclerosis

$113

$117

$122

Coronary atherosclerosis

$12,260

$12,760

$13,258

Non-specific chest pain

$68

$71

$68

Non-specific chest pain

$7,086

$7,367

$7,647

Total

$549

$571

$593

doi:10.1371/journal.pone.0029665.t003
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families from the cost of purchasing cigarettes or the potential for
improved productivity and confidence associated with quitting
smoking.
It is well understood that it is difficult to stop smoking and that
while many may successfully quit in the short- term, there is a
substantial risk of recidivism. While we cannot be assured that
Medicaid beneficiaries who quit smoking remain abstinent in the
long run, there appear to be near-term reductions in smoking rates
that lead to near-term Medicaid savings within the following year
or so. These are conservative estimates given that we only
measured short-term benefits associated with reductions in
inpatient hospital admissions due to cardiovascular conditions.
But program administrators are often most interested in near-term
savings, since they do not know how long beneficiaries will remain
covered by Medicaid and because fiscal concerns lead to pressure
for near-term savings.
Both the federal and state governments share in the costs and
savings related to stronger tobacco cessation efforts for Medicaid
beneficiaries. Although both the federal and state governments are
under substantial budgetary pressure, this research suggests that
further investments in comprehensive tobacco cessation under
Medicaid would be a sound investment that reduces medical
expenditures relatively quickly. As noted earlier, the Patient
Protection and Affordable Care Act already includes efforts to
strengthen tobacco cessation services in Medicaid, including
mandatory coverage of comprehensive services for pregnant
women and enhanced coverage of pharmacotherapy for smoking
cessation. Moreover, Medicaid coverage is scheduled to expand to
serve millions of additional low-income non-elderly adults in 2014
[26]. Thus, tobacco cessation services in Medicaid could soon be
offered to a much larger share of the low-income smoking
population.
Despite the budgetary problems faced by Medicaid program
administrators and state and federal officials, efforts to implement
comprehensive tobacco cessation programs for Medicaid enrollees
(not just those who are pregnant) may be an element of evidencebased policy to both improve public health and reduce health care
expenditures. Because Medicaid provides health insurance coverage, including coverage for preventive services, for a very large
share of a high-risk, low-income population, public health
objectives include recommendations for comprehensive smoking
cessation coverage under Medicaid [4]. Research concerning the
efficacy and cost-effectiveness of these initiatives to encourage
smoking cessation may provide valuable information to policymakers and researchers alike. Additionally, cost-effectiveness
studies that account for heterogeneity in populations of smokers
are needed to provide important information to policymakers and
other key stakeholders.

Table 5. Estimated Net Annual Savings Per User and
Estimated Return on Investment Associated with Reduced
Cardiovascular Admissions among Medicaid Smokers in
Massachusetts (US $ 2010).

Low

Midpoint

High

Net annual savings

$366

$388

$410

Return on investment

$2.00

$2.12

$2.25

doi:10.1371/journal.pone.0029665.t005

variations in the factors associated with expenditures, we
controlled for an extensive set of demographic and health
characteristics and then calibrated these to correspond the risk
profile of Medicaid smokers in Massachusetts, using the BRFSS
data. Our study is also limited by the limitations of Land’s study
[10] which generated estimates of reductions in hospitalization
among Medicaid beneficiaries. That paper discussed its limitations, notably the use of claims data as a proxy for health events
and of the receipt of the tobacco cessation benefit as a proxy for
actual smoking cessation.
A key limitation of our analysis is that we assume that actual
hospital savings are equivalent to the average costs per admission
multiplied by the number of averted hospital admissions. This may
introduce error in two ways. First, it is possible that averted
admissions occur among either healthier or sicker patients who
have lower (or higher) inpatient expenditures. If, for example,
admissions were only averted among healthier patients, more
expensive patients would still be admitted and our estimates would
overstate cost savings. The second source of error is that in
addition to reducing admissions, tobacco cessation programs may
reduce the severity of problems among those admitted. In this
case, there would be additional savings through the result of
reduces expenditures even among those who were hospitalized,
which our study has not captured. Our inclusion of a range of
hospital expenditures, based on the confidence intervals incorporates some of the uncertainty about the actual savings and the
heterogeneity of patient health.
Results from this study are consistent with previous research
which has indicated the efficacy and cost-effectiveness of certain
drug therapies in reducing smoking and the health benefits of
smoking cessation. In particular, it has focused on reductions in
medical expenditures related to hospitalizations for cardiovascular
disease. It did not measure the long-term or lifetime impacts on
medical expenditures. On the other hand, prior analyses have
suggested that smoking cessation may be the most cost-beneficial
long-term strategy for the reduction of the burden of cardiovascular disease in the United States [25].
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